09:30–09:45
Welcome, introductions, and objectives
Confirm the purpose of the kick-off, who is in the room, and the desired outputs from the day.
Draft meeting agenda
TRANsCEnD-CPRD Glasgow kick-off
A two-part agenda for a Thursday project kick-off and a flexible Friday morning follow-up, designed to align the team around the current CPRD work and the next generation of connected projects.
Thursday
Project overview, CPRD protocol, and where-next discussion
09:45–10:45
TRANsCEnD-CPRD project overview and alignment
Orient everyone to the funded CPRD lane before the protocol discussion: project status, governance boundaries, roles, terminology, immediate analytic questions, and how the work relates to ASCEND, ARTEMIS, ORCA, and NEXUS.
10:45–11:30
CPRD protocol discussion — first pass
Walk through the circulated protocol at a practical level, now that everyone has the project context. Identify headline clarification points, owners, pre-read needs, and any immediate protocol questions.
11:30–11:45
Coffee
Break.
11:45–12:30
CPRD protocol discussion — implications and decisions
Continue the protocol discussion with emphasis on what needs deciding before Friday: analysis boundaries, first practical steps, dependencies, and ownership of open questions.
12:30–13:00
Immediate execution plan
Agree the first post-kick-off work block: owner(s), dataset and protocol dependencies, pre-read or follow-up documents, and next check-in.
13:00–13:45
Lunch
Break.
13:45–14:45
Where next? NIHR grant opportunity
Detailed discussion of the potential NIHR grant route: possible aim, fit to TRANsCEnD/CPRD, partners, deliverables, deadline or eligibility constraints, and whether this should become an active workstream.
14:45–15:20
Where next? Rare phenotype identification / fingerprinting
Continue the rare-phenotype identification and fingerprinting discussion: what the scientific claim is, what data or evidence would make it credible, and whether it belongs within TRANsCEnD, adjacent to it, or as a separate follow-on.
15:20–15:40
Future connected work: ORCA, NEXUS, and related AI work
Brief future-facing slot for connected work that may be useful to present: ORCA, NEXUS, EHR-as-language, cross-system translation, and how these might inform later proposals without distracting from the funded CPRD lane.
15:40–15:50
Group and collaborator items
Discussion on team membership and whether there are any additional collaborations that we should consider for the projects discussed.
15:50–16:00
Close: decisions, owners, and Friday morning shape
Confirm decisions, action owners, unresolved questions, and what should be tackled on Friday morning.
Friday morning
Flexible follow-up session
The Friday morning agenda is deliberately left flexible so the group can decide, during Thursday's close, which thread most needs deeper discussion.
09:30–09:45
Re-cap from Thursday
Confirm decisions, open questions, and any overnight reflections.
09:45–10:45
Flexible deep-dive slot 1
Candidate uses: CPRD protocol unresolved points, NIHR grant framing, rare-phenotype / fingerprinting methods, onboarding questions, or ORCA/NEXUS future-work implications. Final choice can be made during Thursday close.
10:45–11:30
Flexible deep-dive slot 2
Continue the most useful thread from slot 1 or split into practical planning: owners, actions, timeline, and pre-reads.
11:30–11:50
Action plan and ownership
Convert the discussion into named actions, deadlines, documents to update, and next meeting or check-in.
11:50–12:00
Close
Confirm what will be circulated after the kick-off and by whom.
Discussion prompts
Where next?
NIHR grant
- What is the strongest fundable question?
- Is TRANsCEnD the right vehicle, or is this a linked proposal?
- What would make the grant distinctive rather than a generic CPRD analysis proposal?
- Who are the minimum necessary partners?
- What is the first concrete drafting step?
Rare phenotype identification / fingerprinting
- What phenotype or patient group is the first credible target?
- What constitutes a “fingerprint” in this setting: code pattern, sequence representation, embedding neighbourhood, model-derived feature, or clinician-interpretable signature?
- What validation would make the result believable?
- Is this an immediate TRANsCEnD work package, a follow-on analysis, or a separate proposal?
Future connected work: ORCA / NEXUS
- Which pieces are mature enough to present as future-facing but credible?
- Which are useful scientific context but should not distract from the funded CPRD protocol?
- Could ORCA or NEXUS supply methods, infrastructure, or a future proposal route for TRANsCEnD?
Group and collaboration items
- Should Ewan Pearson be added to the group or discussion?
- Who should invite or add him, and with what framing?
- Are there other missing collaborators for the NIHR or fingerprinting route?
Expected outputs